Skip to main content

Table 1 Baseline patient characteristics

From: Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand

 

Group I (N = 29)

Group II (N = 70)

Group III (N = 99)

Total (N = 198)

Gender

 Male, n (%)

2 (6.9)

1 (1.4)

2 (2.0)

5 (2.5)

 Female, n (%)

27 (93.1)

69 (98.6)

97 (98.0)

193 (97.5)

Age (years)

 Mean (SD)

66.8 (8.7)

70.1 (8.2)

68.4 (8.4)

68.8 (8.4)

Height (cm)

 Mean (SD)

155.3 (7.2)

151.2 (6.1)

151.4 (6.1)

151.9 (6.4)

Weight (kg)

 Mean (SD)

54.2 (9.0)

51.9 (7.3)

53.3 (8.4)

53.0 (8.2)

  1. Group I: Recent/current bisphosphonate-, strontium-, estrogen-, or SERM-treated patients; Group II: Patients being treated with other drugs; Group III: Treatment-naïve patients. SERM selective receptor estrogen modulator